Incyte — Oct 28, 2025 release

Current Previous Jakafi net product revenues $3,050 - $3,075 million $3,000 - $3,050 million Opzelura net product revenues Unchanged $630 - $670 million Other oncology net product revenues (1) $550 - $575 million $500 - $520 million GAAP Cost of product revenues Unchanged 8.0% - 9.0% of net product revenues Non-GAAP Cost of product revenues (2) Unchanged 7.0% - 8.0% of net product revenues GAAP Research and development expenses Unchanged $1,965 - $1,995 million Non-GAAP Research and development expenses (3) Unchanged $1,815 - $1,840 million GAAP Selling, general and administrative expenses Unchanged $1,280 - $1,310 million Non-GAAP Selling, general and administrative expenses (3) Unchanged $1,160 - $1,185 million 1 Pemazyre in the U.S., EU and Japan; Niktimvo, Monjuvi and Zynyz in the U.S.; and Iclusig and Minjuvi in the EU. 2 Adjusted to exclude the amortization of licensed intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc. and the estimated cost of stock-based compensation. 3 Adjusted to exclude the estimated cost of stock-based compensation. Conference Call and Webcast Information Incyte will hold a conference call and webcast this morning at 8:00 a.m. ET. To access the conference call, please dial 877-407-3042 for domestic callers or 201-389-0864 for international callers. When prompted, provide the conference identification number, 13756261. If you are unable to participate, a replay of the conference call will be available for 90 days. The replay dial-in number for the United States is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To